Table 3.
Association of systemic indices with prostate cancer-specific mortality in men with prostate cancer.
| All Cases | African American | European American | P Heterogeneity | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NLR | Alive N (%) | Dead N (%) | * HR (95% CI) | Alive N (%) | Dead N (%) | * HR (95% CI) | Alive N (%) | Dead N (%) | * HR (95% CI) | |
| Low ≤ 2.9 | 305 (71) | 20 (50) | Ref | 194 (80) | 16 (64) | Ref | 111 (59) | 4 (27) | Ref | |
| High > 2.9 | 126 (29) | 20 (50) | 2.56 (1.25–5.25) | 48 (20) | 9 (36) | 2.96 (1.10–7.98) | 78 (41) | 11 (73) | 2.43 (0.57–10.42) | <0.01 |
| Continuous | 1.51 (1.05–2.18) | 1.40 (0.89–2.22) | 1.84 (0.94–3.59) | |||||||
| PLR | ||||||||||
| Low ≤133.7 | 219 (51) | 14 (35) | Ref | 126 (52) | 10 (40) | Ref | 93 (49) | 4 (27) | Ref | |
| High >133.7 | 211 (49) | 26 (65) | 1.55 (0.74–3.27) | 115 (48) | 15 (60) | 1.75 (0.65–4.74) | 96 (51) | 11 (73) | 1.87 (0.41–8.49) | |
| Continuous | 1.11 (0.68–1.81) | 0.89 (0.44–1.80) | 1.47 (0.71–3.05) | |||||||
| SII | ||||||||||
| Low ≤430.8 | 184 (43) | 9 (22) | Ref | 124 (51) | 8 (32) | Ref | 60 (32) | 1 (7) | Ref | |
| High >430.8 | 246 (57) | 31 (78) | 3.13 (1.37–7.16) | 117 (49) | 17 (68) | 2.63 (1.0–6.97) | 129 (68) | 14 (93) | 11.63 (1.03–131.02) | |
| Continuous | 1.34 (0.96–1.87) | 1.14 (0.77–1.68) | 1.77 (1.00–3.13) | |||||||
| SIRI | ||||||||||
| Low ≤0.9 | 171 (40) | 8 (21) | Ref | 123 (51) | 8 (33) | Ref | 48 (26) | Ref | ||
| High >0.9 | 259 (60) | 31 (79) | 3.24 (1.31–8.06) | 119 (49) | 16 (67) | 3.19 (1.12–9.04) | 140 (74) | 15 (100) | Not enough cases | |
| Continuous | 1.43 (1.11–1.84) | 1.58 (1.11–2.25) | 1.32 (0.84–2.08) | |||||||
* Unconditional Cox regression adjusted for age at study entry, self-reported race (not included in stratified analysis), BMI (kg/m2), aspirin use (no/yes), smoking history (never, former, current), diabetes (no/yes), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, no/yes), and treatment (0 = none, 1 = surgery, 2 = radiation, 3 = hormone, 4 = combination), disease stage (1 = stage I, 2 = stage IIA and IIB, 3 = stage III, 4 = stage IV), Gleason score (0 = Gleason ≤ 7 and 1 = Gleason > 7). CI = confidence interval; HR = hazard ratio.